BOSTON, May 4 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals Corp. will hold its Annual General Meeting of Shareholders and Investor Briefing on Friday May 5, 2006 at 10:00 a.m. EDT. The meeting will be held at the Sheraton Boston Hotel, Back Bay Ballroom, 39 Dalton Street in downtown Boston. An agenda has been posted on the NUCRYST website, www.nucryst.com.
Both the meeting and investor briefing will be webcast live at www.nucryst.com. An audio file of the webcast will be archived and posted on the NUCRYST website.
NUCRYST Pharmaceuticals develops, manufactures and commercializes medical products that fight infection and inflammation using its patented atomically disordered nanocrystalline silver technology. Smith & Nephew plc sell a range of advanced wound care products under their Acticoat(TM) trade mark: Acticoat(TM) products incorporate NUCRYST’s SILCRYST(TM) coatings and are sold in over 30 countries. NUCRYST is also developing pharmaceutical products to address medical conditions that are characterized by both infection and inflammation. The company has developed its nanocrystalline silver in a powder form for use as an active pharmaceutical ingredient, referred to as NPI 32101.
NUCRYST Pharmaceuticals Corp.
CONTACT: Gillian McArdle, (416) 504-8464, info@nucryst.com
